Investigational drug, Plazomicin, for treating multi-drug resistant (MDR) gram-negative infections gets FDA Priority Review

Achaogen, Inc., a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, announced this week that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's New Drug Application (NDA) for plazomicin for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, and bloodstream infections (BSI) due to ["]

The post Investigational drug, Plazomicin, for treating multi-drug resistant (MDR) gram-negative infections gets FDA Priority Review appeared first on Outbreak News Today.